Evidence map›Paper›PMID 22123166›Full record

ReviewNeuroscience2012

Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.

C J Hillard, K M Weinlander, K L Stuhr

Abstract readReview
In one paragraph

Review in Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 6 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 6 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Cannabis-based medicines and medical cannabis for adults with cancer pain.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Cannabis-based medicines for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2018
    Pooled it
  5. Cannabinoids for fibromyalgia.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Pooled it
  7. Trial
  8. The American journal of drug and alcohol abuse · 2019
    Trial
  9. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012
    Trial
  10. Article
  11. Review
  12. Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

C J HillardDepartment of Pharmacology and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, USA. chillard@mcw.edu
K M Weinlander
K L Stuhr
Medical College of Wisconsin · US

Funding

BIOCHEMISTRY OF ANANDAMIDE, AN ENDOGENOUS CANNABINOIDR01DA009155 · NIDA · MEDICAL COLLEGE OF WISCONSIN · PI HILLARD, CECILIA J · 1996 to 2011
$3.4M
Cannabinoid regulation of glycogen synthase kinase-3R01DA026996 · NIDA · MEDICAL COLLEGE OF WISCONSIN · PI HILLARD, CECILIA J · 2010 to 2014
$1.7M
NIDA NIH HHS R01 DA009155NIDA NIH HHS R01 DA026996NIDA NIH HHS R01DA026996NIDA NIH HHS R01DA09155
6 · The paper itself

Abstract

The endocannabinoid signaling system is a widespread, neuromodulatory system in brain and is also widely utilized in the periphery to modulate metabolic functions and the immune system. Preclinical data demonstrate that endocannabinoid signaling is an important stress buffer and modulates emotional and cognitive functions. These data suggest the hypothesis that endocannabinoid signaling could be dysfunctional in a number of mental disorders. Genetic polymorphisms in the human genes for two important proteins of the endocannabinoid signaling system, the CB1 cannabinoid receptor (CB1R) and fatty acid amide hydrolase (FAAH), have been explored in the context of normal and pathological conditions. In the case of the gene for FAAH, the mechanistic relationships among the common genetic polymorphism, the expression of the FAAH protein, and its likely impact on endocannabinoid signaling are understood. However, multiple polymorphisms in the gene for the CB1R occur and are associated with human phenotypic differences without an understanding of the functional relationships among the gene, mRNA, protein, and protein function. The endocannabinoid ligands are found in the circulation, and several studies have identified changes in their concentrations under various conditions. These data are reviewed for the purpose of generating hypotheses and to encourage further studies in this very interesting and important area.

Indexed as

EndocannabinoidsCannabinoid Receptor ModulatorsHumansMental DisordersPolymorphism, GeneticReceptor, Cannabinoid, CB1Signal TransductionCannabinoid Receptor ModulatorsEndocannabinoidsReceptor, Cannabinoid, CB1

Identifiers

PMID22123166
PMCPMC3288440
OpenAlexW1992557727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.